+ Follow SANOFI-SYNTHELABO Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 240420
[Title] => Health info campaign for teens on
[Summary] => The Philippine Obstetrical and Gynecological Society (POGS) and Sanofi-Synthelabo Philippines are spearheading an education campaign for teenagers dubbed "Adolescent Health Issues and Perspectives."
The campaign, which will tackle reproductive health concerns among adolescents, seeks to increase the basic knowledge of sex among the youth who comprises 19.72 percent of the Philippine population. Adolescents are young people between the ages of 10 and 19.
[DatePublished] => 2004-02-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 229446
[Title] => Diabetics face high risk of kidney damage – Study
[Summary] => Results of a recent study show that a high percentage of Filipino patients with type 2 diabetes are at risk of developing kidney damage and cardiovascular disease.
An alarming 73 percent prevalence rate among type 2 diabetics was revealed by Dr. Rosa Allyn Sy, president of the Philippine Diabetes Association (PDA), in a recent media briefing held in Quezon City.
"The results should awaken everyone, particularly health professionals involved in diabetes care, that diabetes mellitus is a silent killer," Sy said.
[DatePublished] => 2003-11-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 197872
[Title] => Cervical cancer screening drive on
[Summary] => Obstetricians and gynecologists have identified various risk factors that are closely linked to cervical cancer. Among the most common risk factors are early sexual contact, having multiple sex partners, and having sex partners who are infected with the human papilloma virus.
"Early initiation into sex is a predisposing factor that leads to cervical cancer," says Dr. Lyra Ruth Clemente-Chua, president of the Philippine Obstetrical and Gynecological Society (POGS).
[DatePublished] => 2003-03-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 195248
[Title] => Drive vs cervical cancer stepped up
[Summary] => The Philippine Obstetrical and Gynecological Society (POGS) and Sanofi-Synthelabo Phils. inked yesterday a memorandum of agreement aimed at intensifying efforts to promote proper feminine health care as a preventive measure in the fight against cervical cancer.
[DatePublished] => 2003-02-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 147972
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[5] => Array
(
[ArticleID] => 147162
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 146353
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 145603
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[8] => Array
(
[ArticleID] => 145286
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
SANOFI-SYNTHELABO
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 240420
[Title] => Health info campaign for teens on
[Summary] => The Philippine Obstetrical and Gynecological Society (POGS) and Sanofi-Synthelabo Philippines are spearheading an education campaign for teenagers dubbed "Adolescent Health Issues and Perspectives."
The campaign, which will tackle reproductive health concerns among adolescents, seeks to increase the basic knowledge of sex among the youth who comprises 19.72 percent of the Philippine population. Adolescents are young people between the ages of 10 and 19.
[DatePublished] => 2004-02-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 229446
[Title] => Diabetics face high risk of kidney damage – Study
[Summary] => Results of a recent study show that a high percentage of Filipino patients with type 2 diabetes are at risk of developing kidney damage and cardiovascular disease.
An alarming 73 percent prevalence rate among type 2 diabetics was revealed by Dr. Rosa Allyn Sy, president of the Philippine Diabetes Association (PDA), in a recent media briefing held in Quezon City.
"The results should awaken everyone, particularly health professionals involved in diabetes care, that diabetes mellitus is a silent killer," Sy said.
[DatePublished] => 2003-11-27 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 197872
[Title] => Cervical cancer screening drive on
[Summary] => Obstetricians and gynecologists have identified various risk factors that are closely linked to cervical cancer. Among the most common risk factors are early sexual contact, having multiple sex partners, and having sex partners who are infected with the human papilloma virus.
"Early initiation into sex is a predisposing factor that leads to cervical cancer," says Dr. Lyra Ruth Clemente-Chua, president of the Philippine Obstetrical and Gynecological Society (POGS).
[DatePublished] => 2003-03-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 195248
[Title] => Drive vs cervical cancer stepped up
[Summary] => The Philippine Obstetrical and Gynecological Society (POGS) and Sanofi-Synthelabo Phils. inked yesterday a memorandum of agreement aimed at intensifying efforts to promote proper feminine health care as a preventive measure in the fight against cervical cancer.
[DatePublished] => 2003-02-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 147972
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[5] => Array
(
[ArticleID] => 147162
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 146353
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 145603
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2002-01-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[8] => Array
(
[ArticleID] => 145286
[Title] => Sanofi-Synthelabo and Cephalon ink agreement
[Summary] => Sanofi-Synthelabo and Cephalon recently announced that they have signed a collaboration agreement to develop and market angiogenesis inhibitors.
This agreement includes a number of orally active molecules that are based upon Cephalon's proprietary kinase inhibitor technology.
[DatePublished] => 2001-12-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
abtest
February 26, 2004 - 12:00am
November 27, 2003 - 12:00am
February 13, 2003 - 12:00am
January 22, 2002 - 12:00am
January 15, 2002 - 12:00am
January 8, 2002 - 12:00am
January 1, 2002 - 12:00am
December 29, 2001 - 12:00am
